Zöllner, Johann Philipp
Misselwitz, Björn
Kaps, Manfred
Stein, Marco
Konczalla, Jürgen
Roth, Christian
Krakow, Karsten
Steinmetz, Helmuth
Rosenow, Felix
Strzelczyk, Adam
Article History
Received: 2 November 2019
Accepted: 13 February 2020
First Online: 2 March 2020
Competing interests
: J.P.Z. reports a speaker’s honorarium from Eisai. F.R. reports personal fees from Eisai, GW Pharmaceuticals, and Desitin Arzneimittel; personal fees and others from Novartis; personal fees from Medtronic; personal fees from Cerbomed; personal fees from Shire; and grants from the European Union, the German Minister for Education and Research (BMBF), the LOEWE Programm of the state of Hessen, the Deutsche Forschungsgemeinschaft (DFG), and the Detlev-Wrobel-Fonds for Epilepsy Research. A.S. reports personal fees and/or grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix. None of the other authors reports conflicts of interest.